Guangzhou TV: innovative medicine renews hope as Reforgene's gene editing drug achieves clinical cure in a girl with severe thalassemia
On November 6, 2023, the news channel of Guangzhou Television broadcast an interview with Reforgene and Sun Yat-sen Memorial Hospital of Sun Yat-sen University, reporting on the breakthrough progress of the recent successful cure of a beta-thalassemia patient with the innovative gene editing medicine RM001. This internationally leading benchmark drug development achievement is a vivid example of the high-quality development of biomedicine in the Greater Bay Area.
"Guangdong is a high-incidence region for thalassemia, with one in every six people on average carrying a thalassemia gene. The province's first child with severe beta-thalassemia treated with gene editing technology has recently achieved clinical cure. Reported by Zheng Hanjing." Reporter: Zheng Hanjing. Source: Guangzhou TV.
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com · BD@reforgene.com